{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:23:21Z","timestamp":1789899801818,"version":"4.0.1"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"23","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Influenza virus neuraminidase (NA) drug resistance is one of the challenges to preparedness against epidemic and pandemic influenza virus infections. NA N1- and N2-containing influenza viruses are the primary cause of seasonal epidemics and past pandemics. The structural and functional basis underlying drug resistance of the influenza virus N1 NA is well characterized. Yet drug resistance of the N2 strain is not well understood. Here, we confirm that replacement of N2 E119 or I222 results in multidrug resistance, and when the replacements occur together, the sensitivity to NA inhibitors (NAI) is reduced severely. Using crystallographic studies, we showed that E119 replacement results in a loss of hydrogen bonding to oseltamivir and zanamivir, whereas I222 replacement results in a change in the hydrophobic environment that is critical for oseltamivir binding. Moreover, we found that MS-257, a zanamivir-oseltamivir hybrid inhibitor, is less susceptible to drug resistance. The binding mode of MS-257 shows that increased hydrogen bonding interactions between the inhibitor and NA active site anchor the inhibitor within the active site and allow adjustments in response to active-site modifications. Such stability is likely responsible for the observed reduced susceptibility to drug resistance. MS-257 serves as a next-generation anti-influenza virus drug candidate and serves also as a scaffold for further design of NAIs.<\/jats:p><jats:p><jats:bold>IMPORTANCE<\/jats:bold>Oseltamivir and zanamivir are the two major antiviral drugs available for the treatment of influenza virus infections. However, multidrug-resistant viruses have emerged in clinical cases, which pose a challenge for the development of new drugs. N1 and N2 subtypes exist in the viruses which cause seasonal epidemics and past pandemics. Although N1 drug resistance is well characterized, the molecular mechanisms underlying N2 drug resistance are unknown. A previous report showed that an N2 E119V\/I222L dual mutant conferred drug resistance to seasonal influenza virus. Here, we confirm that these substitutions result in multidrug resistance and dramatically reduced sensitivity to NAI. We further elucidate the molecular mechanism underlying N2 drug resistance by solving crystal structures of the N2 E119V and I222L mutants and the dual mutant. Most importantly, we found that a novel oseltamivir-zanamivir hybrid inhibitor, MS-257, remains more effective against drug-resistant N2 and is a promising candidate as a next-generation anti-influenza virus drug.<\/jats:p>","DOI":"10.1128\/jvi.01703-16","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T02:29:21Z","timestamp":1474511361000},"page":"10693-10700","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor"],"prefix":"10.1128","volume":"90","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"},{"name":"Center for Influenza Research and Early-warning, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"},{"name":"University of Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"Qi","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhai","family":"Bi","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"},{"name":"Center for Influenza Research and Early-warning, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Fu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Li","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mario","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Vavricka","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po","family":"Tien","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Gao","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"},{"name":"National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"},{"name":"Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China"},{"name":"Center for Influenza Research and Early-warning, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.2008.007260-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2009.00103.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/518936"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msm103"},{"key":"e_1_3_2_6_2","first-page":"109","article-title":"Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses","volume":"18","author":"Hurt AC LS","year":"2012","unstructured":"Hurt AC LS, Speers DJ, Barr IG, Maurer-Stroh S. 2012. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 18:109\u2013112.","journal-title":"Emerg Infect Dis"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00151-12"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00296-10"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1512.091057"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/4371108a"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01339-05"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2067"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/135965350601100804","article-title":"Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds","volume":"11","author":"Abed Y","year":"2006","unstructured":"Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971\u2013976.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05114"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1909"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00805-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep01551"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2013.144"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002249"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00638-11"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.51.1.407"},{"key":"e_1_3_2_22_2","first-page":"1741","article-title":"Update: influenza A (H3N2)v transmission and guidelines\u2014five states, 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Update: influenza A (H3N2)v transmission and guidelines\u2014five states, 2011. MMWR Morb Mortal Wkly Rep 60:1741\u20131744.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_23_2","first-page":"1213","article-title":"Swine-origin influenza A (H3N2) virus infection in two children\u2014Indiana and Pennsylvania, July\u2013August 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Swine-origin influenza A (H3N2) virus infection in two children\u2014Indiana and Pennsylvania, July\u2013August 2011. MMWR Morb Mortal Wkly Rep 60:1213\u20131215.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_24_2","first-page":"1615","article-title":"Limited human-to-human transmission of novel influenza A (H3N2) virus\u2014Iowa, November 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Limited human-to-human transmission of novel influenza A (H3N2) virus\u2014Iowa, November 2011. MMWR Morb Mortal Wkly Rep 60:1615\u20131617.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06956"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002914"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01608-09"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/508777"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.0058"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.5.3385-3390.1997"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.0058"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200102000-00002"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16934-1"},{"key":"e_1_3_2_34_2","first-page":"p 23","volume-title":"Second International Symposium on Influenza and other Respiratory Viruses","author":"Carr J","year":"2000","unstructured":"Carr J, Ives J, Roberts NA, Tai CY, Mendel DB, Kelly L, Lambkin R, Oxford J. 2000. An oseltamivir treatment-selected influenza A\/Wuhan\/359\/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo, p 23. In Second International Symposium on Influenza and other Respiratory Viruses. The Macrae Group, New York, NY."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.0078"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-10"},{"key":"e_1_3_2_37_2","first-page":"7377","article-title":"Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors","volume":"53","author":"Mohan S","year":"2010","unstructured":"Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. 2010. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J Med Chem 53:7377\u20137391.","journal-title":"Binding to N1 enzymes in the context of virus-like particles. J Med Chem"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.03.180"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep02871"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.03.039"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444999008379"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0021889897006766"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444996012255"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444902016657"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444904019158"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0021889892009944"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3403-3408.2001"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(79)90362-2"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00959-08"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.017"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/318537"},{"key":"e_1_3_2_52_2","article-title":"Lead optimization for medicinal chemists","author":"D\u00f6rwald FZ","year":"2012","unstructured":"D\u00f6rwald FZ. 2012. Lead optimization for medicinal chemists. Wiley-VCH, Weinheim, Germany.","journal-title":"Wiley-VCH, Weinheim, Germany"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01426-12"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/656439"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.23.19884-en"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01703-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01703-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T23:45:31Z","timestamp":1657323931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.01703-16"}},"subtitle":[],"editor":[{"given":"A.","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":54,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1128\/JVI.01703-16"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01703-16","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}